Element Biosciences

The firm reported approximately $60 million in revenues in 2024, more than double the amount it recorded in the prior year.

Both short-read and long-read instrument makers are fleshing out their multiomics menus as they hope to gain a share of the fast-evolving market.

The past year was difficult for many life science tools companies but not all doom and gloom for some single-cell and spatial omics firms.